L3VLUP
ProSign in

VCEL · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

VCELGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • VCEL
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterVCELGILD
Q3 20202 holders, $6.8m25 holders, $14.2bn
Q4 20203 holders, $19m27 holders, $13.4bn
Q1 20216 holders, $68m24 holders, $14.5bn
Q2 20213 holders, $37m18 holders, $14.9bn
Q3 20212 holders, $5.0m20 holders, $16.4bn
Q4 20211 holders, $2.1m20 holders, $16.8bn
Q1 2022none listed holders, n.a.28 holders, $13.2bn
Q2 20221 holders, $1.3m26 holders, $13.6bn
Q3 2022none listed holders, n.a.24 holders, $13.3bn
Q4 2022none listed holders, n.a.32 holders, $21.1bn
Q1 20231 holders, $27m27 holders, $21.8bn
Q2 20231 holders, $19m24 holders, $20.7bn
Q3 20232 holders, $21m24 holders, $20.0bn
Q4 20231 holders, $479k22 holders, $21.5bn
Q1 20242 holders, $1.6m30 holders, $20.3bn
Q2 20241 holders, $1.0m28 holders, $18.5bn
Q3 20241 holders, $1.0m29 holders, $24.2bn
Q4 20242 holders, $2.7m28 holders, $25.9bn
Q1 20253 holders, $32m33 holders, $32.0bn
Q2 20252 holders, $40m27 holders, $30.9bn
Q3 20254 holders, $37m23 holders, $29.4bn
Q4 20253 holders, $11m25 holders, $34.3bn
Q1 20261 holders, $1.3m25 holders, $38.5bn
Q2 20262 holders, $14m26 holders, $34.2bn
VCEL

Vericel Corp

Holders
3
Reported value
$11m
Buyers
16
Sellers
17

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
25
Reported value
$34.3bn
Buyers
18
Sellers
19

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2025

Among the 26 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only VCEL (1)

PDT Partners LLC

Only GILD (23)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Dodge & Cox, Fidelity (FMR LLC), Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →